Molecular Partners AG
MLLCF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.17 | 0.01 | -0.01 | 0.49 |
| FCF Yield | -48.43% | -52.31% | 63.27% | -16.50% |
| EV / EBITDA | -1.21 | -0.85 | 0.84 | -8.13 |
| Quality | ||||
| ROIC | -41.10% | -33.01% | 47.36% | -49.94% |
| Gross Margin | -855.81% | -579.80% | 73.68% | -489.07% |
| Cash Conversion Ratio | 1.10 | 0.95 | 1.01 | 1.43 |
| Growth | ||||
| Revenue 3-Year CAGR | -70.29% | -8.97% | 172.73% | -22.93% |
| Free Cash Flow Growth | -0.26% | -151.06% | 226.98% | -200.85% |
| Safety | ||||
| Net Debt / EBITDA | 1.19 | 1.07 | -0.69 | 1.08 |
| Interest Coverage | -2,448.68 | -1,247.10 | 192.75 | -115.73 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -288.41 | -2,290.00 |
| Cash Conversion Cycle | 185.21 | 87.37 | -5.29 | 973.98 |